Navigation Links
SENOMYX ANNOUNCES EXTENSION OF DISCOVERY AND DEVELOPMENT COLLABORATION WITH CADBURY PLC
Date:7/7/2008

SAN DIEGO, CA, July 7, 2008 /PRNewswire-FirstCall/ -- Senomyx, Inc. (Nasdaq: SNMX), a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage and ingredient supply industries, announced today a one-year extension of its exclusive collaborative research and license agreement with Cadbury Adams USA LLC, a unit of Cadbury plc, for the discovery and commercialization of new flavor ingredients in the gum confectionery area. Under the terms of the extended agreement, Cadbury has agreed to pay Senomyx research funding and specified payments upon the achievement of milestones during the collaborative period. Upon commercialization, Senomyx will receive royalty payments based on sales of products using the new flavor ingredients.

"Senomyx's collaboration with Cadbury has been ongoing since July 2005, and we are pleased to extend our partnership for an additional year," said Kent Snyder, President, Chief Executive Officer, and Chairman of the Board of Senomyx. "Cadbury is currently the world's largest confectionery company with gum brands such as Trident, Dentyne, Hollywood and Bubbaloo. We believe their decision to continue our collaboration reflects our excellent working relationship and is an endorsement of Senomyx's innovative technology and the commercial potential of our programs," Snyder noted.

About Senomyx, Inc. (http://www.senomyx.com)

Senomyx is a leading company using proprietary taste receptor technologies to discover and develop novel flavor ingredients in the savory, sweet, salt, bitter, and cooling areas. Senomyx has entered into product discovery and development collaborations with seven
'/>"/>

SOURCE Senomyx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Senomyx Announces Conclusion of Discovery and Development Collaboration With Kraft Foods Global, Inc.
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
5. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
6. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
7. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...IK,Iceland,November24/PRNewswire-FirstCall/--deCOD...hasreceivednoticefrom,theNasdaqStockMarketthattrad...vember30,2009andaForm25-NSEwillbefiledwiththe,Secu...scommonstock,fromlistingonNasdaq,unlessthecompanyf....Thecompanyhasfiledsuchanappeal,which,willstaythes...
(Date:11/24/2009)... Health care employment grew by 29,000...ne to show consistent growth during the U.S. reces...ain in trouble, and health systems are coming clos...stead of just administrators. , ...ployment continued growing in October despite the ...
(Date:11/24/2009)...I,Nov.24/PRNewswire-Asia/--NODPharmaceuticalsInc.a...lowedthepatentapplicationfor,itsnano-particleorald...hlyefficientapproachtoincorporatepeptidesor,protei...ryofdrugs,otherwiseadministeredasinjections.NODtec...ymacromoleculardrugssuchasinsulin,interferon,grow...
(Date:11/24/2009)...I,Nov.24/PRNewswire-Asia/--ShanghaiBiolaxyannounce...hasapprovedthe,investigationalnewdrugapplication(I...nsulinformulationtotreatdiabetes.ThisIND,approvala... , Diabetesisadisordercharacteristicofhighblo...etesoftenresultinseveremicro-and,macro-vasculardis...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2
...ollowing was issued,today by the Greater Baltimore...O, Greater Baltimore Committee, 140 company owner...rea,bioscience community, WHAT:, The third annua...N:, Tuesday, March 18, 2008, 8:00 a.m. / Breakfa...ram, WHERE:, Renaissance Harborplace Hotel, 202 ...
...rocess, Drive Value from Appraisals, OTTAWA, Marc...ng,provider of web-based employee performance and ... has been selected by Quiznos to provide a system,...adquarters. Quiznos is a,national chain with over ...usy consumers who are looking for a tasty, fresher...
...d Support of National Electronic Disease ...Calif., March 17 Computer,Sciences Corporation (N...ed a,task order from the Centers for Disease Contr... supporting the National Electronic Disease,Survei...m helps the CDC,manage and enhance public health s...
Other Biology Technology:Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2Quiznos Selects Halogen for Fresh Approach to Talent Management 2CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order 2
(Date:11/25/2009)... may be just as vital to your health as what you e...ological Studies. Their experiments in mice reveal...f genes in the liverthe body,s metabolic clearingh... the body,s circadian clock as conventional wisdom...vity of a large number of genes completely indepen...
(Date:11/24/2009)...and flabby arteries from collapsing have been true...re no longer needed -- once the arteries are stren...ors had no choice but to leave them in place. , ...partment of Biomedical Engineering has developed a...ugs where they,re needed, then dissolves. , "Our...
(Date:11/24/2009)...d is a matter of debate. A high-profile study a fe...ent of their carbon from trees and leaves, evidenc...d aquatic ecosystems. , But new research from th...y to be true. Algae provide a much richer diet for...h published this week in the Proceedings of the N...
Breaking Biology News(10 mins):Feeding the clock 2Feeding the clock 3A coating for life 2Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 14439 1AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 14439 2AMT Receives EMEA Orphan Drug Designation for Duchenne Muscular Dystrophy 14439 3DC 3A Muslim Coalition to Host Interfaith Hearing on Health Care 59326 1DC 3A Muslim Coalition to Host Interfaith Hearing on Health Care 59326 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 4Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 5Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 6Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 7Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 8
...g bones, a healthy immune system, protection again...ere,s yet another item for the expanding list of v...n," keeps the heart, the body,s long-distance runn...gan pharmacologist Robert U. Simpson, Ph.D., think...er." , In studies in rats, Simpson and his team ...
...11, 2008 The J. David Gladstone Institutes today ..., MD, PhD, also of Kyoto University and UCSF, has ...ntributions in reprogramming adult skin cells to p...eive half of the $1 million award. Cloning pioneer...er half of the prize for their landmark generation...
...ational May Concern Law Enforcement Departments, ...ulletin Board: STIY), the leader in electro-stun t...sting law enforcement departments that,have purcha...ade their,weapons in for Stinger S-200 electronic ...ssions., Ron Bellistri, Stinger,s CEO, stated, "I...
Other Biology News:Vitamin D: New way to treat heart failure? 2Vitamin D: New way to treat heart failure? 3Gladstone's Shinya Yamanaka wins prestigious Shaw Prize 2Stinger Systems To Offer Taser Trade-In Program 2
Mouse Anti-Xanthine Oxidase Prediluted Monoclonal Antibody, Unconjugated, Clone SPM325 from Abcam
Mouse Anti-Vancomycin Monoclonal Antibody, Unconjugated, Clone 2G1 from Abcam
Mouse Anti-14-3-3 Binding Motif, phospho (Ser) Monoclonal Antibody, Unconjugated, Clone 4E2 from Cell Signaling Technology
Endotoxin Free Water from Mo Bio Laboratories, Inc.
Biology Products: